Cadrenal Therapeutics, Inc. Common Stock (CVKD)
Healthcare
Biotechnology
2.00 $
-3.8%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Cadrenal Therapeutics, Inc. Common Stock (CVKD)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 79.4% of the shares are freely tradable; institutional investors hold 6.0%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
6.0%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
16.0%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
79.4%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
2.8%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
3Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Group Inc | 1.75 | 53,912 | -0.6 | 12/31/2025 |
| Vanguard Capital Management, LLC | 1.47 | 45,201 | +0.0 | 03/31/2026 |
| Geode Capital Management, LLC | 0.70 | 21,626 | +48.9 | 03/31/2026 |
| Vanguard Fiduciary Trust Co | 0.27 | 8,311 | +0.0 | 03/31/2026 |
| JPMorgan Chase & Co | 0.24 | 7,500 | +0.0 | 03/31/2026 |
| BlackRock Inc | 0.18 | 5,496 | +56.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Vanguard Total Stock Mkt Idx Inv | 1.08 | 33,278 | +0.0 | 04/30/2026 |
| Fidelity Extended Market Index | 0.48 | 14,646 | -0.4 | 04/30/2026 |
| Vanguard Institutional Extnd Mkt Idx Tr | 0.39 | 11,923 | +0.0 | 04/30/2026 |
| Abante Quant Value FI | 0.22 | 6,875 | +0.0 | 03/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.